Introduction {#s1}
============

Swine influenza is a respiratory disease caused by multiple subtypes of influenza A virus (IAV). The genome of IAV consists of eight segments, which code for different virus proteins. Subtype classification of IAV is based on the encoded surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), and so far, 16 different HA and nine different NA subtypes have been described together with two recently discovered bat-derived subtypes, H17N10 and H18N11 (Cheung and Poon, [@B7]; Wu et al., [@B23]). Influenza A virus contains further six "internal" gene segments which encode basic polymerase 2 (PB2), basic polymerase 1 (PB1), acidic polymerase (PA), nucleoprotein (NP), matrix (M1, M2), and non-structural proteins (NS1, NS2). These segments and their translation products have an essential role in the virulence and host specificity of a given IAV and can also impact the risk of transmission to humans (Bi et al., [@B3]).

The predominant swine IAV (swIAV) subtypes globally are H1N1, H3N2, and H1N2, which all show considerable diversity. The genetic and antigenic characteristics of IAVs in pigs differ depending on their geographic locations (Kuntz-Simon and Madec, [@B13]; Simon et al., [@B17]). In Europe, the dominant H1N1 swIAV is of avian origin, referred to as avian-like swine H1N1 (H1~av~N1~av~), which was introduced from waterfowl to pigs in the late 1970s (Pensaert et al., [@B16]; Simon et al., [@B17]). The dominant genotype of H3N2 virus in European pigs is the H3N2 (H3~sw~N2~sw~) virus that was introduced in 1984. The HA and NA genes of the H3~sw~N2~sw~ are of human origin, while the other six gene segments are of avian (H1~av~N1~av~) descent (Castrucci et al., [@B6]). In 1994, an H1N2 reassortant was isolated for the first time in United Kingdom and has subsequently been detected in many European countries. This human-like reassortant swine H1N2 (H1~hu~N2~sw~) virus comprised the HA gene from a human seasonal H1N1 virus, the NA gene from the H3~sw~N2~sw~ virus and internal genes from the H1~av~N1~av~ virus (Alexander et al., [@B1]). The dominating European H1~hu~N2~sw~ virus has never been detected in Denmark, however, a new reassortant H1~av~N2~sw~, containing the HA gene from the H1~av~N1~av~ virus and the NA gene from H3~sw~N2~sw~, was found in Denmark in 2003 (Trebbien et al., [@B21]). This avian-like H1N2 (H1~av~N2~sw~) virus has become established in Denmark and other European countries (Trebbien et al., [@B21]; Simon et al., [@B17]) and is now the most prevalent subtype circulating in Danish pigs. In 2009, a new human pandemic strain \[A(H1N1)pdm09\] entered the global swine population and is now enzootic in swine globally. Furthermore, an increasing number of reassortants between the predominant enzootic swIAVs and the A(H1N1)pdm09 virus have been observed, making subtyping of swIAV a very complex task (Starick et al., [@B20]; Watson et al., [@B22]). Furthermore, spillover of seasonal human H3 (H3~hu~) segments and human N2 (N2~hu~) have been observed in Danish swine (Breum et al., [@B5]; Krog et al., [@B12]).

In Denmark, a passive surveillance program for swIAVs has been conducted since 2011. A requirement for efficient swIAV surveillance is highly sensitive and specific diagnostic tests. Today, the swIAV screening test and subsequent subtyping is performed by reverse transcription (RT) quantitative real-time PCR (qPCR), where several different assays are needed to cover the wide range of circulating subtypes, which make detection and subtyping costly and time consuming. The aim of the present study was to establish a high-throughput method for detection and subtyping of swIAVs in Danish pigs. The BioMark dynamic array (DA) (Fluidigm, South San Francisco, USA) is capable of performing parallel qPCRs by combining e.g., 48 samples with 48 assays or 96 samples with 96 assays in a combinatorial manner inside the integrated fluidic circuit (IFC) resulting in either 2,304 or 9,216 individual reactions in a single run. Besides being able to process a high number of reactions in a single run, the high-throughput qPCR BioMark system also uses less sample and reagent volume compared to standard qPCR platforms (Spurgeon et al., [@B19]). The present study describes the design, optimization and validation of a swIAV 48.48DA; a setup consisting of 18 qPCR assays targeting the different swIAVs circulating in Europe.

Materials and methods {#s2}
=====================

Samples
-------

In the routine veterinary diagnostic laboratory at the National Veterinary Institute in Denmark, oral fluid, lung tissue, and nasal swabs are tested for swIAV from pigs with a history of respiratory disease. The samples are tested by an in-house modified RT-qPCR assay detecting the M gene (Trebbien et al., [@B21]). For selected swIAV positive samples, virus is isolated in Madin-Darby Canine Kidney (MDCK) cell cultures, followed by full genome sequencing by Next Generation Sequencing (NGS) (Krog et al., [@B12]). For validation of the swIAV 48.48DA a total of 32 field samples from 2015 and 2016 (Table [1](#T1){ref-type="table"}) and 29 virus isolates for which full genome sequences were available were used (Table [2](#T2){ref-type="table"}).

###### 

HA and NA subtyping of swIAV from Danish field samples by swIAV 48.48DA.

  **Sample name**                    **Origin[^a^](#TN1){ref-type="table-fn"}**   **Subtype[^b^](#TN2){ref-type="table-fn"}**                                         **Singleplex[^c^](#TN3){ref-type="table-fn"}**   **swIAV 48.48DA[^d^](#TN4){ref-type="table-fn"}**                                                                                                                      
  ---------------------------------- -------------------------------------------- --------------------------------------------- ------------------------------------- ------------------------------------------------ --------------------------------------------------- ------------ ------------ ------------- -------- ------------ ------------ ------------- ------------ ------------ ------------
                                                                                  **HA**                                        **NA**                                **M**                                            **M**                                               **H1~av~**   **H1~hu~**   **H1~pdm~**   **H3**   **N1~B1~**   **N1~B2~**   **N1~pdm~**   **N2~B1~**   **N2~B2~**   **N2~hu~**
  **A/Swine/Denmark/7961-7/2016**    ?                                            H1pdm                                         N1pdm                                 21                                               22.41                                                                         27.18                  27.87        21.09        **24.52**     **30.66**                 
  A/Swine/Denmark/9186-1/2016        ns                                           H1pdm                                         N1pdm                                 29.57                                            28.73                                                                         22.53                  25.84        29.97        29.45                                   
  A/Swine/Denmark/10130-1/2016       ns                                           H1pdm                                         N1pdm                                 22                                               22.53                                                                         19.95                  21.58        22.25        21.43                                   
  A/Swine/Denmark/16219-1/2016       ?                                            H1pdm                                         N1pdm                                 23                                               25.90                                                                         23.57                  25.93        26.49        26.92                                   
  A/Swine/Denmark/16966-2/2016       ?                                            H1pdm                                         N1pdm                                 25.85                                            26.34                                                                         24.11                  24.96        25.46        26,99                                   
  A/Swine/Denmark/19295-1/2015       lu                                           H1pdm                                         N1pdm                                 21.50                                            21.43                                                                         15.93                  18.76        19.80        19.53                                   
  A/Swine/Denmark/19089-3/2015       lu                                           H1pdm                                         N1pdm                                 21                                               22.24                                                                         18.97                  19.27        20.27        21.66                                   
  A/Swine/Denmark/19090-1/2015       lu                                           H1pdm                                         N1pdm                                 24                                               25.58                                                                         20.05                  25.63                     23.61                                   
  A/Swine/Denmark/20835-1/2015       ?                                            H1pdm                                         N1pdm                                 24                                               23.78                                                                         23.83                  21.52        22.32        22.18                                   
  A/Swine/Denmark/6521-1/2016        ns                                           H1pdm                                         N2sw                                  27                                               24.99                                                                         26.42                                                          28.24        32.63        
  **A/Swine/Denmark/7988-2/2016**    lu                                           H1pdm                                         N2sw                                  18                                               18.50                                               **27.74**                 **22.10**                                                      24.92        25.79        
  A/Swine/Denmark/9154-4/2016        ns                                           H1pdm                                         N2sw                                  26.44                                            26.18                                                                         23.28                                                          27.83        32.56        
  A/Swine/Denmark/20566-1/2015       ns                                           H1pdm                                         N2sw                                  19                                               19.10                                                                         14.89                                                          26.71        31.26        
  A/Swine/Denmark/10856-3/2016       ns                                           H1av                                          N1                                    26                                               25.72                                               31.59                                            29.11                                                             
  A/Swine/Denmark/23293-4/2015       ns                                           H1av                                          N1                                    25                                               24.47                                               32.85                                            25.02        26.57                                                
  **A/Swine/Denmark/8938-1/2015**    ns                                           H1av                                          N?![](fcimb-08-00165-i0001.jpg)N1     31                                               25.53                                               23.91                                                         24.95                                                
  A/Swine/Denmark/6392-2/2016        ns                                           H1av                                          N2sw                                  21.39                                            23.45                                               22.64                                                                                    26.43                     
  A/Swine/Denmark/6469-1/2016        lu                                           H1av                                          N2sw                                  20                                               21.94                                               28.10                                                                                    27.24                     
  A/Swine/Denmark/6534-3/2016        lu                                           H1av                                          N2sw                                  15.87                                            18.78                                               18.18                                                                                    22.06                     
  **A/Swine/Denmark/6598-1/2016**    sa                                           H1av                                          N2sw                                  29                                               26.30                                               28.91                                                                                                              
  A/Swine/Denmark/6637-1/2016        ns                                           H1av                                          N2sw                                  25                                               25.68                                               25.54                                                                                    25.26                     
  **A/Swine/Denmark/6686-1/2015**    ns                                           H?![](fcimb-08-00165-i0001.jpg)H1av           N2sw                                  30                                               25.25                                               24.09                                                                                                 34           
  A/Swine/Denmark/8065-1/2016        ns                                           H1av                                          N2sw                                  22                                               23.62                                               24.37                                                                                                 28.77        
  A/Swine/Denmark/9051-1/2016        lu                                           H1av                                          N2sw                                  18.75                                            20.92                                               19.80                                                                                    25.17        29.47        
  A/Swine/Denmark/9846-1/2016        ns                                           H1av                                          N2sw                                  25.84                                            25.35                                               25.24                                                                                    29.89                     
  A/Swine/Denmark/11013-3/2016       lu                                           H1av                                          N2sw                                  14                                               14.34                                               16.52                                                                                    17.67        20.67        
  **A/Swine/Denmark/14170-2/2016**   ?                                            H1av                                          N?![](fcimb-08-00165-i0001.jpg)N2sw   25.41                                            23.51                                               23.95                                                                                    27.94        31.68        
  A/Swine/Denmark/15963-2/2016       ?                                            H1av                                          N2sw                                  23                                               22.49                                               20.97                                                                                    30.70        28.21        
  A/Swine/Denmark/19292-1/2015       ns                                           H1av                                          N2sw                                  26.45                                            25.67                                               23.78                                                                                    30.37        31.93        
  A/Swine/Denmark/19293-1/2015       lu                                           H1av                                          N2sw                                  16.27                                            17.24                                               15.38                                                                                    21.31        25.04        
  A/Swine/Denmark/23653-3/2015       ns                                           H1av                                          N2sw                                  27.49                                            25.35                                               24.25                                                                                    30.94        33.87        
  **A/Swine/Denmark/9079-2/2016**    lu                                           H?                                            N2sw                                  27.31                                            26.39                                                                                                                                        37.51                     

*ns, nasal swab; lu, lung tissue; sa, oral fluid; ?, unknown*.

*Subtype achieved by an in house multiplex RT-qPCR (modified from Henritzi et al., [@B8])*.

*Cq-value achieved by an in-house modified RT-qPCR assay detecting the M gene (Trebbien et al., [@B21])*.

*Cq-value achieved by swIAV 48.48DA*.

*Samples where a discrepancy was observed between the two analyses are in bold letter*.

###### 

Parallel subtyping of virus isolates by full genome sequencing (left) and qPCR using the swIAV 48.48DA (right).

![](fmicb-08-00165-i0002)

*Samples where a discrepancy was observed between the two analyses are in bold letter*.

Primer and probe design
-----------------------

The swIAV 48.48DA was designed to include qPCR assays targeting the different lineages of H1, H3, N1, and N2 circulating in pigs in Europe. For the H1 subtypes the design aimed at differentiating between the H1 lineages; H1~av~, H1 from A(H1N1)pdm09 (H1~pdm~) and H1~hu~. For the H3 lineages the aim was to differentiate between H3~sw~ and H3~hu~. For the NA subtypes N1 and N2 broadly reacting assays (N1~B1~, N1~B2~, N2~B1~, N2~B2~) were included together with an assay specifically detecting the A(H1N1)pdm09 lineage of N1 (N1~pdm~) and an assay specifically detecting N2~hu~ derived from the seasonal human H3N2, that circulated in humans in the mid-1990s. Accordingly, N1~pdm~ positive viruses gave positive results with the N1~B1~, N1~B2~ and N1~pdm~ assays, while N2~hu~ positive viruses gave positive results with the N2~B1~, N2~B2~ and N2~hu~ assays.

In addition, six qPCR assays specific for the internal genes of A(H1N1)pdm09 (PB1~pdm~, PB2~pdm~, PA~pdm~, NP~pdm~, M~pdm~, NS~pdm~) were included. Primers and probes were either selected from previously published methods or designed in the present study. The final sets of primers and probes consisting of 18 PCR assays, of which 12 were designed *de novo*, two were from published literature, three were modified published assays and one was an in-house assay. The modifications are highlighted in bold in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}. New primer and probe sequences were designed based on alignments comprising full-length sequences of the eight gene segments from European swIAVs. The sequences were retrieved from Influenza Research Database[^1^](#fn0001){ref-type="fn"} The specificity of primers and probes was tested *in silico* by using BLAST search (Altschul et al., [@B2]), while melting temperature of the oligonucleotides was approximated using the online tool "OligoCalc" (Kibbe, [@B10]). The RT-qPCR assays were tested on the Rotor-Gene Q qPCR system (QIAGEN, Hilden, Germany) using a panel of six strains of cultured viruses, representing targets for one or more of the different primer and probe sets. RT-qPCR assays were performed in a final volume of 25 μL using QIAGEN OneStep RT-PCR kit (QIAGEN), with 5 μL of 5X QIAGEN One step RT-PCR buffer, 1 μL of 10 mM nucleotides dNTP mix, 1.25 μL of 25 mM MgCl~2~, 1 μL of 100 μM primers, 0.25 μL of 30 μM probe, 1 μL QIAGEN enzyme mix, 2 μL RNA and 12.5 μL RNase-free water. Thermal cycling conditions were as follow: 50°C for 30 min, 95°C for 15 min followed by 40 cycles at 94°C for 10 s, 54°C for 30 s and 72°C for 10 s. The fluorescence signal was acquired at the 54°C step in the Green channel (470--510 nm). Data was analyzed with the Rotor-Gene Q Series Software 2.3.1. (QIAGEN) with the following parameter adjustments: dynamic tube normalization, on; noise slope correction, on; ignore first cycle; outlier removal, 10%; quantification cycle (Cq) threshold fixed, 0.01. All reactions were run in duplicates and non-template control (nuclease-free water) was included in each run.

###### 

Primers and probes for detection of M, HA, and NA genes.

  **Primer/probe**                             **Sequence (5′-3′)**                                     **Product size (bp)**   **References**
  -------------------------------------------- -------------------------------------------------------- ----------------------- ------------------------------------------------------------------------
  **H1**~av~                                                                                                                    Modified from (Henritzi et al., [@B8])[^a^](#TN5){ref-type="table-fn"}
  H1~av~-F                                     GAAGGRGGATGGACAGG**A**AT**G**A                           139                     
  H1~av~-R                                     CAATTAHTGARTTCACTTTGTTG**CTG**                                                   
  H1~av~-P                                     **FAM**-TCTGGTTACGCAGCWGATCAGAAAA-BHQ1                                           
  **H1**~hu~                                                                                            169                     Primer: This study
  H1~hu~-F                                     GGWTGGTATGGTTATCATCAT                                                            Probe: (Bonin et al., [@B4])
  H1~hu~-R                                     CTCGATTACAGAGTTCACC                                                              
  H1~hu~-P                                     FAM-CAGGGATCTGGCTATGCTGCAGAYC-BHQ1                                               
  **H1**~pdm~                                                                                           87                      In-house assay
  H1~pdm~-F                                    AGTTCAAGCCGGAAATAGCA                                                             
  H1~pdm~-R                                    CCCGGCTCTACTAGTGTCCA                                                             
  H1~pdm~-P                                    FAM-CCCAAAGTGAGGRATCAAGAAGGGAG-BHQ1                                              
  **H3**~hu~                                                                                            93                      This study
  H3~hu~-F                                     TGATGGAGAAAACTGCACACTA                                                           
  H3~hu~-R                                     CGTTCAACAAAAAGGTCCCATTTC                                                         
  H3~hu~-P                                     FAM-CACACTGAGGGTCTCCCAATAGAGCATCTA-BHQ1                                          
  **H3**~sw~                                                                                            93                      This study
  H3~sw~-F                                     TGATGGAGCAAATTGCACACTG                                                           
  H3~sw~-R                                     CGTTCAATGAAAAGGTCCCATTTC                                                         
  H3~sw~-P                                     FAM-CACAATGAGGGTCCCCTAATAGAGCGTCCA-BHQ1                                          
  **N1**~B1~                                                                                            99                      This study
  N1~B1~-F                                     CCTTGCTTCTGGGTTGAACTAATC                                                         
  N1~B1~-R                                     AGTGTCACTATTTACACCACAAAAGG                                                       
  N1~B1~-P                                     FAM-TGCTCCCGCTAGTCCAGATTGTGTTCTCTT-BHQ1                                          
  **N1**~B2~                                                                                            126                     Henritzi et al., [@B8]
  N1~B2~-F                                     AGRCCTTGYTTCTGGGTTGA                                                             
  N1~B2~-R                                     ACCGTCTGGCCAAGACCA                                                               
  N1~B2~-P                                     FAM-ATYTGGACYAGTGGGAGCAGCAT-BHQ1                                                 
  **N1**~pdm~                                                                                           102                     This study
  N1~pdm~-F                                    CGAAATGAGTGCCCCTAATTATC                                                          
  N1~pdm~-R                                    CGATTCGAGCCATGCCAGTTA                                                            
  N1~pdm~-P[^\*^](#TN6){ref-type="table-fn"}   FAM-\[+C\]\[+C\]T\[+G\]ATTCT\[+A\]GTGAAATCA\[+C\]-BHQ1                           
  **N2**~B1~                                                                                            101                     This study
  N2~B1~-F                                     TATTGATGAATGAGTTGGGTGTTCC                                                        
  N2~B1~-R                                     ATGCAGCCATGCTTTTCCATC                                                            
  N2~B1~-P                                     FAM-TGAACTGGACCATGCTATACACACTTGCCT-BHQ1                                          
  **N2**~B2~                                                                                            116                     Modified from (Henritzi et al., [@B8])[^a^](#TN5){ref-type="table-fn"}
  N2~B2~-F                                     AGTCTGGTGGACYTCAAAYAG                                                            
  N2~B2~-R                                     TTGCGAAAGCTTATATAGVCATGA                                                         
  N2~B2~-P                                     **FAM**-CCATCAGGCCATGAGCCTGWWCCATA-BHQ1                                          
  **N2**~hu~                                                                                            92                      This study
  N2~hu~-F                                     CTGGTATTTTCTCTGTTGAAGGC                                                          
  N2~hu~-R                                     CCASACTTCAKTTTCCTGYTTCC                                                          
  N2~hu~-P[^\*^](#TN6){ref-type="table-fn"}    VIC-T\[+C\]A\[+A\]CTCYACATAAAAGCACC\[+G\]-BHQ1                                   
  **M**                                                                                                 204                     (Loeffen et al., [@B14])
  M-F                                          CTTCTAACCGAGGTCGAAACGTA                                                          
  M-R                                          CACTGGGCACGGTGAGC                                                                
  M-P                                          FAM-TCAGGCCCCCTCAAAGCCGA-BHQ1                                                    

*Letters in bold in the sequences indicate the modification compared to the published sequences*.

*Locked Nucleic Acid positions are indicated in brackets*.

###### 

Primers and probes for detection of the internal pandemic genes of swIAVs.

  **Primer/probe**   **Sequence (5′-3′)**                     **Product size (bp)**   **References**
  ------------------ ---------------------------------------- ----------------------- ----------------
  **PB2**~pdm~                                                                        
  PB2~pdm~-F         GATAGTAAGCGGGAGAGAC                      128                     This study
  PB2~pdm~-R         GCTGGTTTGCCCTATTGAC                                              
  PB2~pdm~-P         FAM-GCTGAGGCAATAATTGTGGCCATGG-BHQ1                               
  **PB1**~pdm~                                                                        
  PB1~pdm~-F         CAAAGACTACAGATACACATATAG                 124                     This study
  PB1~pdm~-R         ATCTGATACTAATAGCCCTAC                                            
  PB1~pdm~-P         FAM-GGGGAGACACACAAATTCAGACGAG-BHQ1                               
  **PA**~pdm~                                                                         
  PA~pdm~-F          GGTGAAAATATGGCACCAGAA                    110                     This study
  PA~pdm~-R          TGCTAGAGATCTGGGCTC                                               
  PA~pdm~-P          FAM-GTAGACTTTGATGAYTGCAAAGATGTTGG-BHQ1                           
  **NP**~pdm~                                                                         
  NP~pdm~-F          ACGGTCAGCACTCATTCTG                      117                     This study
  NP~pdm~-R          ACCAGTGAGTACCCTTCC                                               
  NP~pdm~-P          FAM-TCATGCCCACTTGCTACTGCAAGC-BHQ1                                
  **M**~pdm~                                                                          
  M~pdm~-F           CTGGCTAGCACTACRGCA                       99                      This study
  M~pdm~-R           TACCATYTGCCTAGTCTGATTA                                           
  M~pdm~-P           FAM-CTCYATGGCCTCTGCTGCCTGT-BHQ1                                  
  **NS**~pdm~                                                                         
  NS~pdm~-F          GAGGAAATGTCACGAGACTG                     119                     This study
  NS~pdm~-R          ACTGAAGTTCGCTTTCAGTAC                                            
  NS~pdm~-P          FAM-TTCCATGACCGCCTGGTCCAATCG-BHQ1                                

Primers and the dual labeled probes were purchased from Eurofins Genomics (Ebersberg, Germany), while Locked Nucleic Acid (LNA) probes were from BioNordika (Herlev, Denmark). Primers and probes were stored at −20°C.

RNA extraction
--------------

Viral RNA was extracted from cultured viruses, oral fluid, lung tissue and nasal swab samples by RNeasy Mini Kit (QIAGEN) according to the manufacturer\'s instructions. Cell culture supernatant, oral fluid and nasal swab samples were prepared by mixing 200 μL material with 400 μL RLT buffer containing β-mercaptoethanol (Sigma-Aldrich, Brøndby, Denmark). Lung tissue samples were prepared by homogenization of 70 mg lung tissue in 1,400 μL RLT buffer containing β-mercaptoethanol (Sigma-Aldrich) on a TissueLyser II (QIAGEN) at 30 Hz in 3 min. The homogenate was centrifuged for 3 min at 12,000 g, and RNA was extracted from of 600 μL of the supernatant. Viral RNA was eluted in 60 μL RNase-free water and stored at −80°C.

cDNA synthesis and pre-amplification
------------------------------------

cDNA synthesis and pre-amplification of the extracted samples was performed in one step. Briefly, reaction volumes of 25 μL containing 1.50 μL of 10 μM random hexamer (Invitrogen, Carlsbad, California, USA), 0.75 μL primer mix (containing all qPCR primers (200 nM each) listed in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}), 5 μL of 5X QIAGEN One step RT-PCR buffer (QIAGEN), 1 μL of 10 mM nucleotides dNTP mix, 1.25 μL of 25 mM MgCl~2~, 1 μL QIAGEN enzyme mix, 3 μL sample and RNase-free water were prepared. cDNA synthesis and pre-amplification were performed on a T3 Thermocycler (Biometra, Fredensborg, Denmark) at 50°C for 30 min followed by enzyme inactivation at 95°C for 15 min followed by 24 cycles of 94°C for 10 s, 54°C for 30 s, and 72°C for 10 s. The pre-amplified cDNA was stored at −20°C.

Preparation of the 48.48DA and qPCR
-----------------------------------

Pre-sample mix was prepared using the following components per sample; 3 μL TaqMan Gene Expression Master Mix (Applied Biosystems, Foster city, USA) and 0.3 μL 20x Sample loading reagent (Fluidigm, South San Francisco, USA). Pre-sample mix (3.3 μL) was mixed with 2.7 μL pre-amplified cDNA. Two different mixes of primers and probes with different concentrations, was prepared for each assay by mixing 3 μL primer/probe-stock (containing either 30 μM of each primer and 6.8 μM of probe or 33 μM of each primer and 10 μM of probe) with 3 μL 2X Assay loading reagent (Fluidigm). qPCR was performed in a BioMark 48.48DA (Fluidigm) combining 48 pre-amplified samples with 48 assays for 2304 individual and simultaneous qPCR reactions. The 48.48DA was primed in the IFC controller MX (Fluidigm) prior to loading of samples and assays. Sample mix (4.9 μL), and primer mix (4.9 μL) was dispensed into inlets on the 48.48DA, which was again placed in the IFC controller for loading and mixing of the 48 samples and 48 assays. After approximately 55 min the 48.48DA was ready for thermal cycling in the high-throughput qPCR instrument BioMark (Fluidigm) with the following cycling conditions: 15 min at 95°C, followed by 40 cycles at 94°C for 10 s, at 54°C for 30 s, and 72°C for 10 s. Non-template controls were included to control non-specific amplification and sample contamination. Specificity and sensitivity of all assays were tested against six virus isolates, representing targets for one or more of the different assays and thus the virus isolates functioned as both positive and negative controls for the individual primer and probe sets. Data (Cq-values and amplification curves) were acquired on the BioMark system and analyzed using the Fluidigm Real-Time PCR Analysis software 4.1.3 (Fluidigm).

Validation of sensitivity of the qPCR assays
--------------------------------------------

To test and compare the performance and dynamic range of the qPCR assays on the Rotor-Gene Q platform and on the high-throughput qPCR BioMark platform, RNA 10-fold serial dilutions from six different swIAV isolates were tested on the Rotor-Gene Q, and the same RNA dilutions were cDNA synthesized and pre-amplified and then tested on the BioMark. Furthermore, 10-fold serial dilutions were made from the pre-amplified cDNA from the six swIAV isolates and these were only tested on the BioMark platform.

Verification of the specificity of the swIAV 48.48DA
----------------------------------------------------

The performance of the swIAV 48.48DA was verified by testing 32 field samples (nasal swabs, oral fluid, and lung tissue samples) and 29 virus isolates (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). The full genome sequences were known for the virus isolates (Supplementary Table [1](#SM1){ref-type="supplementary-material"}), while only the type of HA and NA genes were known for the field samples. The field samples have previously been tested and subtyped by an in-house multiplex RT-qPCR (modified from Henritzi et al., [@B8]) for diagnostic purposes.

Data availability statement
---------------------------

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Results {#s3}
=======

Specificity and sensitivity of the qPCR assays
----------------------------------------------

RNA obtained from a panel of six IAVs of subtype H1, H3, N1, and N2 of avian, human, or porcine origin was used to evaluate the sensitivity and specificity of the different sets of primers and probes. The specificity of each assay was assessed from the Cq-value obtained from their respective target in relation to any cross reaction. For all qPCR assays, specific positive reactions were registered and no cross reactions were observed (Figure [1](#F1){ref-type="fig"}). The 18 selected assays discriminated correctly between the different linages of the HA gene (H1~av~, H1~hu~, H1~pdm~, H3~hu~, H3~sw~) and NA gene (N1~av~, N1~pdm~, N2~sw~, N2~hu~). The qPCR assays specific for the internal genes discriminated in all cases between the pandemic and non-pandemic genes (Figure [1](#F1){ref-type="fig"}). Series of 10-fold diluted RNA of the six virus isolates were tested on the Rotor-Gene Q and on the swIAV 48.48DA to assess the relative analytical sensitivity of the qPCR assays. Comparisons of the Cq-values of the dilutions revealed that, in general, the dynamic range of the assays was 2--5 log~10~ for the swIAV 48.48DA and four-six log~10~ for the Rotor-Gene system (Table [5](#T5){ref-type="table"}). For some of the assays the undiluted sample was not tested due to too small amount of available sample material. The dynamic range of the qPCR assays was generally 1--2 log higher using the Rotor-Gene Q compared to the swIAV 48.48DA. Ten-fold serial dilutions of the pre-amplified cDNA resulted in similar dynamic range and efficiency as the RNA dilutions for each of the qPCR assays (data not shown).

![Heat map showing the specificity of the qPCR assays included on the swIAV 48.48DA by testing six virus isolates with known subtype (based on full genome sequencing). Top: The qPCR assays (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}) in two different primer/probe concentrations (indicated by the numbers two or four). Left: The virus isolates and a Non-Template Control (NTC). Each square corresponds to a single real-time PCR reaction. Cq-values for each reaction are indicated by color; the corresponding color scale is presented in the legend on the right. A black square is considered as a negative result.](fcimb-08-00165-g0001){#F1}

###### 

Relative sensitivity of qPCR assays on the Rotor-Gene Q platform and on the swIAV 48.48DA (BioMark platform).

                 **Assays**                                                                                                                                                                   
  -------------- ---------------- -------------- ---------------- ------------- ---------------- ------------- ---------------- ------------- ---------------- ------------- ---------------- -------------
  **Dilution**   **H1~av~**       **H1~hu~**     **H1~pdm~**      **H3~hu~**    **H3~sw~**       **M**                                                                                        
                 **Rotor-Gene**   **BioMark**    **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**
  10             14.20            17.29^\*^      15.57            17.40         14.58            13.44         \-               17.71         13.93            14.22         \-               11.85
  10^−1^         18.60            23.79          19.03            22.46         17.56            17.98         22.87            21.22         17.05            16.87         14.06            17.33
  10^−2^         22.69            28.12          22.66            26.03         20.79            19.98         25.81            23.78         20.44            19.43         17.00            22.01
  10^−3^         25.75            31.49          25.88            29.13         24.17            23.64         29.43            27.53         24.04            24.07         20.34            23.69
  10^−4^         28.86            neg            29.30            neg           27.20            28.88         32.70            neg           28.16            28.27         24.09            27.81
  10^−5^         32.66            neg            32.42            neg           30.97            neg           35.28            neg           neg              neg           27.53            29.45
  10^−6^         neg              neg            neg              neg           34.22            neg           neg              neg           neg              neg           29.96            neg
  10^−7^         neg              neg            neg              neg           neg              neg           neg              neg           neg              neg           neg              neg
  Effectivity    0.89             0.80           0.98             0.80          1.01             0.88          1.07             1.04          0.91             1.01          1.02             0.84
  **Dilution**   **N1~B1~**       **N1~B2~**     **N1~pdm~**      **N2~B1~**    **N2~B2~**       **N2~hu~**                                                                                   
                 **Rotor-Gene**   **BioMark**    **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**
  10             18.09            15.15          19.14            17.21         18.04            16.24         14.54            15.53^\*^     12.47            15.34         12.70            7.73
  10^−1^         22.05            19.69          22.42            21.55         21.01            20.73         17.15            21.35         16.20            21.08         14.71            12.81
  10^−2^         25.77            21.55          25.17            23.91         25.15            22.39         20.19            25.74         19.03            25.81         18.35            16.88
  10^−3^         29.50            25.57          28.76            27.14         28.75            26.79         23.36            29.32         22.00            28.78         22.28            18.95
  10^−4^         32.70            29.25          32.22            29.67         31.26            28.40         26.43            32.32         24.89            30.83         26.50            21.70
  10^−5^         36.33            neg            35.76            neg           neg              neg           30.93            neg           29.31            neg           30.25            23.58
  10^−6^         neg              neg            neg              neg           neg              neg           neg              neg           neg              neg           34.42            neg
  10^−7^         neg              neg            neg              neg           neg              neg           neg              neg           neg              neg           neg              neg
  Effectivity    0.89             1.01           1.00             1.02          0.96             1.07          1.04             0.89          1.04             0.82          0.89             1.11
  **Dilution**   **PB2~pdm~**     **PB1~pdm~**   **PA~pdm~**      **NP~pdm~**   **NS~pdm~**      **M~pdm~**                                                                                   
                 **Rotor-Gene**   **BioMark**    **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**   **Rotor-Gene**   **BioMark**
  10             15.32            13.79          \-               19.67         \-               18.49         \-               \-            \-               16.45         13.81            12.58
  10^−1^         20.13            16.78          22.08            22.91         17.88            21.76         18.22            17.25         17.26            20.35         16.82            17.14
  10^−2^         25.27            19.31          24.62            25.85         22.12            24.67         21.59            20.97         20.30            23.26         20.62            20.16
  10^−3^         27.6             22.35          27.74            29.02         24.94            28.27         24.88            25.09         23.80            26.06         24.46            24.36
  10^−4^         29.95            26.87          31.53            32.14         28.19            32.56         29.11            27.68         27.16            28.18         27.93            28.07
  10^−5^         neg              29.49          34.65            neg           32.61            neg           32.18            neg           30.64            neg           30.53            neg
  10^−6^         neg              neg            37.43            neg           neg              neg           neg              neg           neg              neg           33.67            neg
  10^−7^         neg              neg            neg              neg           neg              neg           neg              neg           neg              neg           neg              neg
  Effectivity    0.87             1.00           1.07             1.09          0.93             0.94          0.92             0.89          0.98             1.06          0.98             0.82

Validation of the swIAV 48.48DA chip
------------------------------------

In order to validate the performance of the swIAV 48.48DA for subtyping of swIAVs, a total of 29 well-characterized virus isolates and 32 field samples were tested. The subtype of the samples had previously been determined by either full genome sequencing or multiplex RT-qPCR and the results obtained by the swIAV 48.48DA were compared to these findings (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

Of the 29 virus isolates, which have previously been full genome sequenced, 27 showed identical results when the subtyping was performed on the swIAV 48.48DA and by sequencing (Table [2](#T2){ref-type="table"}). For each of the remaining two isolates there was a discrepancy for one of the genes. By full genome sequencing, the M gene of A/Swine/Denmark/4790-1/2015 had 93% identity with both pandemic and non-pandemic M genes of Danish swIAV strains (results not shown). The sample gave a positive signal for M~pdm~ on the swIAV 48.48DA despite that there were two mismatches in the primer and probe bindings regions and was by that defined as M~pdm~. The NP gene of A/Swine/Denmark/03627-2/2015 was subtyped as being of non-pandemic origin by the swIAV 48.48DA, while based on the full genome sequence analysis the NP gene was found to be pandemic. The sequence analysis also revealed one mismatch in the binding site of the reverse primer and two mismatches between the probe binding sites for the NP~pdm~ assay. Thus, these mutations could explain the discrepancy between the results obtained by sequencing and by test on the swIAV 48.48DA. Another sample, A/Swine/Denmark/ 20566-1/2015, was found to have the subtype H1~pdm~N2~sw~ with pandemic internal genes in both the full genome sequencing and when tested on the swIAV 48.48DA. However, this sample also tested positive in the assay specific for the H1~av~ gene (Table [2](#T2){ref-type="table"}). Retesting of the sample on the Rotor-Gene Q in the H1~av~ and H1~pdm~ assays confirmed these results, indicating that this sample contained two different viruses.

Field samples (*n* = 32), consisting of nasal swabs, lung tissue or oral fluid, were also analyzed on the swIAV 48.48DA (Table [1](#T1){ref-type="table"}). These samples had previously been subtyped by an in-house multiplex RT-qPCR assay (modified from Henritzi et al., [@B8]), thus only the HA and NA genes were known for these samples. The heat map in Figure [2](#F2){ref-type="fig"} shows the results of a subset of the tested field samples in which the subtype for each of the sample was clarified based on the Cq-value and on the accuracy of the corresponding amplification curve. The swIAV 48.48DA and the multiplex RT-qPCR revealed the same HA type for 30 of the samples. However, none of the qPCR methods could define the HA subtype of sample A/Swine/Denmark/9079-2/2016. Furthermore, the HA subtype was not defined by the multiplex RT-qPCR for sample A/Swine/Denmark/6686-1/2015, but it was successfully determined using the swIAV 48.48DA. The sample A/Swine/Denmark/7988-2/2016 was found positive in both the H1~av~ and H1~pdm~ assay by the swIAV 48.48DA, but only positive for H1~pdm~ in the multiplex RT-qPCR. Therefore, this sample was further tested in the H1~av~ and H1~pdm~ assays on the Rotor-Gene Q, where it was found positive in both assays indicating infection with two different viruses. For the NA assays, 29 of 32 samples were found to have the same NA linage by both qPCR typing methods. For the sample A/Swine/Denmark/6598-1/2016 no signal was obtained in any of the NA assays on the swIAV 48.48DA, while it was positive in the N2~B2~ assay in the multiplex RT-qPCR. The sample was also tested in the N2 assay on the Rotor-Gene Q, where it was found to be weakly positive, with a Cq-value around 30. For the samples A/Swine/Denmark/14170-2/2016 and A/Swine/Denmark/8938-1/2015, no NA signal was obtained in the multiplex RT-qPCR, while the swIAV 48.48DA detected a signal in the N2~B1~ and N2~B2~ assays and in the N1~B2~, respectively. The swIAV 48.48DA found sample A/Swine/Denmark/7961-7/2016 to be of both N1~pdm~ and N2~sw~ origin, while this sample was only positive in the N1~pdm~ assay when using the multiplex RT-qPCR. Additional test on the Rotor-Gene Q found also this sample to be positive in the N2~B1~ assay---again indicating that the samples contained two different viruses.

![Heat map showing the results of a subset of the tested field samples on the swIAV 48.48DA. Top: The HA, NA, and M specific assays in two different primer/probe concentrations (indicated by the numbers two or four). Left: number 11--44 (except for number 22) is the tested field samples in duplicates, number 47 is a negative control for the cDNA-pre.amp setup and number 22 and 48 is Non-Template Controls (NTC). Each square corresponds to a single real-time PCR reaction. Cq-values for each reaction are indicated by color; the corresponding color scale is presented in the legend on the right. A black square is considered as a negative result.](fcimb-08-00165-g0002){#F2}

In summary, when comparing the results for the swIAV 48.48DA with the sequencing and multiplex RT-qPCR results for the virus isolates and field samples, fully matching subtyping results (based on HA and NA genes) were obtained for 57 (29 virus isolates and 28 field samples) of 61 tested samples, and three of the 57 samples also showed an additional subtype in the analysis with the swIAV 48.48DA indicating a double infection. Furthermore, when comparing the number of positive findings in the gold-standard tests (sequencing and multiplex RT-qPCR) with the swIAV 48.48DA test an agreement was observed for nine of the tested genes, while a difference between 1.2 and 4.9 % was observed for the rest of the genes (Table [6](#T6){ref-type="table"}).

###### 

Comparison of the number of positive findings using the gold-standard test compared to the swIAV 48.48DA (BioMark) test (percentage in parentheses).

  **Genes**   **Gold-standard test**   **swIAV 48.48DA (BioMark)**
  ----------- ------------------------ -----------------------------
  H1~av~      32/61 (52.5%)            35/61 (57.4%)
  H1~pdm~     26/61 (42.6%)            26/61 (42.6%)
  H3~sw~      0/61 (0%)                0/61 (0%)
  H3~hu~      1/61 (1.6%)              1/61 (1.6%)
  N1          7/61 (11.5%)             8/61 (13.1%)
  N1~pdm~     14/61 (23.0%)            14/61 (23.0%)
  N2          34/61 (55.7%)            35/61 (57.4%)
  N2~hu~      4/61 (6.6%)              4/61 (6.6%)
  PB2~pdm~    19/29 (65.5%)            19/29 (65.5%)
  PB1~pdm~    18/28 (64.3%)            19/29 (65.5%)
  PA~pdm~     19/29 (65.5%)            19/29 (65.5%)
  M~pdm~      20/29 (69.0%)            20/29 (69.0%)
  NP~pdm~     20/29 (69.0%)            19/29 (65.5%)
  NS~pdm~     19/29 (65.5%)            19/29 (65.5%)

Discussion {#s4}
==========

The BioMark high-throughput qPCR protocol for detection and expanded subtyping of influenza virus in pigs described in the present paper proved to be as specific and sensitive as standard state-of the art diagnostic methods based on "conventional" qPCR and sequencing. This new approach makes it possible to combine multiple assays and samples and run them simultaneously. It requires less labor and pipetting, leading to an economical benefit. Another benefit is the use of nanolitre volume chambers in the DA, in contrast to conventional qPCR that uses microliter, thereby decreasing the use of expensive reagents. The BioMark high-throughput qPCR system has for years been widely used in research studies i.e., for the study of innate immune response to pathogens (Skovgaard et al., [@B18]). More recently, high-throughput qPCR protocols using the BioMark platform have also been designed as surveillance tools for tick-borne diseases and for food- and waterborne pathogens (Ishii et al., [@B9]; Michelet et al., [@B15]). Similar to the present study, Ishii et al. ([@B9]) found the system to offer highly sensitive and specific simultaneous quantification of multiple food-and waterborne pathogens in multiple samples (Ishii et al., [@B9]). The platform is a flexible tool because it is easy to modify the assay panel by adding or removing primers or probes when new pathogens or new variants emerge (Ishii et al., [@B9]; Michelet et al., [@B15]).

To our knowledge this is the first paper describing the use of the BioMark high-throughput qPCR platform for detection and subtyping of influenza viruses. In general, there was a high degree of agreement for the results provided by multiplex RT-qPCR or sequencing and the results generated by the swIAV 48.48DA. For a few of the tested samples, there was a discrepancy. These differences could be explained by either co-infection with two viruses or by mismatches in the primer/probe binding regions. Thus, imperfect match between the target sequence and the primer and/or probe sequences can result in a false-negative signal even though the sample is positive for swIAV. This emphasizes that the swIAV 48.48DA or multiplex RT-qPCR protocols cannot stand alone as a subtyping method, but has to be combined with a continuous surveillance by sequencing of circulating swIAV isolates. Due to the high mutation- and reassortant rate of IAVs (Simon et al., [@B17]) it is important to do continuous sequencing of selected isolates because changes will occur over time and it is necessary to adjust the PCR assays accordingly. Sequencing is a very informative tool and it can contribute with indispensable information about evolutionary relationships based on similarities and differences between the sequences. However, since the number of isolates that can be sequenced is limited by practical and economic reasons, the swIAV 48.48DA provides an excellent screening tool for selection of atypical isolates for downstream characterization by sequencing.

Pre-amplification of the RNA samples was needed because of the very small sample volumes (\< 10 nL; Korenková et al., [@B11]) in the reaction chambers. This is in accordance with recommendations from the supplier and previous studies using the BioMark protocols for the detection of i.e., water-borne pathogens (Ishii et al., [@B9]). The supplier of the BioMark platform recommends performing the cDNA synthesis and pre-amplification as two separate steps. However, we managed to change this into a one-step procedure by combining the cDNA synthesis and pre-amplification, which further reduced the analysis costs and the number of handling steps. A benefit of this alteration is also the reduced risk of contamination due the fewer handling steps. The swIAV 48.48DA was tested against a panel of representative virus isolates in order to assess the sensitivity and specificity. All the assays had an acceptable PCR efficiency between 80 and 110%. Comparison of the assay performance on the two qPCR platforms; Rotor-Gene Q and BioMark, revealed only a minor difference in the dynamic range and efficiency for all the assays. For a majority of the qPCRs, the dynamic range was one-two log~10~ higher on the Rotor-Gene Q platform compared to the BioMark. This might be a result of the considerable lower reaction volume in the 48.48DA (\< 10 nL) compared to the tubes (25 μl) of the Rotor-Gene Q. No cross reactions were observed for any of the assays on the swIAV 48.48DA, which testifies a high specificity. To test the specificity in more detail, virus isolates and field samples, which have previously been subtyped by sequencing or multiplex RT-qPCR, were tested on the swIAV 48.48DA. Again no cross reactions were observed and the three field samples, which failed to provide a signal in the HA or NA analysis in the multiplex RT-qPCR test, were subtyped by the swIAV 48.48DA. This difference can be explained by the ability of the swIAV 48.48DA to subtype weakly positive samples (Cq-value of 30 or above in the M qPCR assay) which cannot be subtyped using the standard multiplex RT-qPCR protocol. The improved sensitivity of the swIAV 48.48DA is related to the 24 pre-amplification cycles used prior to the PCR step.

The heat map generated by the Fluidigm Real-Time PCR Analysis software illustrates the raw Cq-values for each reaction, which makes is feasible to quickly evaluate which subtype the individual samples have (Figure [2](#F2){ref-type="fig"}). Using the swIAV 48.48DA for the subtyping of swIAVs in surveillance programs, will make the analysis more simple compared to the traditional subtyping methods and it will give a more detailed subtyping of the samples since the internal genes are included in the analysis.

In summary, the use of the swIAV 48.48DA will allow future subtyping of many more influenza virus isolates for the same resources and by that contribute to a more sensitive surveillance program and provide the basis for an improved early detection of new virus re-assortments and variants. The high sensitivity, specificity and robustness of the test system may also provide an opportunity for development of other similar chips i.e., for the surveillance and diagnose of other veterinary pathogens. Work is in progress on the development of a 48.48DA containing all important swine pathogens for the use in future surveillance and diagnostic programs in Danish swine herds.
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